When to Resume Apixaban After Appendectomy
Resume apixaban 24 hours after appendectomy if it was a straightforward, uncomplicated procedure with adequate hemostasis, or wait 48-72 hours if there were any bleeding concerns or complications during surgery.
Bleeding Risk Classification
Appendectomy is typically classified as a low-to-moderate bleeding risk procedure when uncomplicated (simple laparoscopic or open appendectomy without significant inflammation or perforation). However, it becomes a high bleeding risk procedure if complicated by perforation, abscess, or significant inflammation requiring extensive dissection 1.
Resumption Timing Based on Surgical Complexity
For Uncomplicated Appendectomy (Low Bleeding Risk)
- Resume apixaban 5 mg twice daily starting 24 hours after surgery 1
- This timing allows sufficient time for initial wound hemostasis while minimizing thrombotic risk
- The FDA label supports restarting "as soon as adequate hemostasis has been established" 2
For Complicated Appendectomy (High Bleeding Risk)
- Delay resumption to 48-72 hours postoperatively 1, 3
- Consider starting with a reduced dose of apixaban 2.5 mg twice daily for the first 2-3 days in patients at high thrombotic risk, then increase to full dose (5 mg twice daily) 1
- This stepwise approach balances bleeding risk against thrombotic protection
Special Considerations for High Thrombotic Risk Patients
If your patient has high thrombotic risk (mechanical heart valve, recent stroke/TIA within 3 months, CHADS₂ score ≥3), consider:
- Using prophylactic-dose LMWH (enoxaparin 40 mg daily) for the first 24-72 hours postoperatively
- Then transitioning to reduced-dose apixaban (2.5 mg twice daily) before advancing to full therapeutic dosing 1
- Do NOT use bridging anticoagulation with therapeutic-dose LMWH when restarting apixaban, as this significantly increases bleeding risk without reducing thrombotic events 4, 5
Critical Assessment Before Resumption
Before restarting apixaban, verify:
- Adequate surgical hemostasis - no ongoing bleeding, stable hemoglobin, no expanding hematomas
- Surgical drain output (if present) is minimal and non-bloody
- No signs of intra-abdominal bleeding - stable vital signs, no abdominal distension, no peritoneal signs
- Bowel function returning - apixaban requires oral absorption, though this is less critical than with dabigatran 1
Common Pitfalls to Avoid
Do not restart too early with full therapeutic dosing after complicated surgery - the rapid onset of action (peak levels in 1-3 hours) means immediate anticoagulation similar to therapeutic LMWH 1
Do not use bridging therapy - apixaban's rapid onset makes bridging unnecessary and dangerous, increasing bleeding risk 3-fold without reducing thrombotic events 4, 5
Do not assume all appendectomies are the same - perforated appendicitis with peritonitis or abscess formation requires the high-bleeding-risk protocol 6, 7
Consider renal function - while apixaban has only 25% renal clearance (better than dabigatran's 80%), patients with CrCl <30 mL/min may have prolonged drug levels and require extended interruption 1, 8
Practical Algorithm
Day of Surgery (Day 0): Surgery performed, apixaban held
Postoperative Day 1 (24 hours):
- Uncomplicated appendectomy with good hemostasis → Resume apixaban 5 mg BID
- Complicated appendectomy or bleeding concerns → Hold, consider prophylactic LMWH
Postoperative Days 2-3 (48-72 hours):
- Complicated cases with now-adequate hemostasis → Resume apixaban 2.5 mg BID (if high thrombotic risk) or 5 mg BID (if standard risk)
Postoperative Day 4+:
- Advance to full therapeutic dose (5 mg BID) if started on reduced dose
The evidence consistently supports this risk-stratified approach across multiple high-quality guidelines 1, 3, 4, with the 2022 ACCP guidelines providing the most recent comprehensive framework 4.